Fexuprazan not checked
Daewoong Pharmaceutical Co. LTD. · DWP14012
FollowEvery change as it happens, and a Monday email
Trials
3 active
16 in total
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Fexuprazan 20mg placebo-matching tablet, orally, once daily for up to 24 weeks”In the company’s words, NCT07533266 on ClinicalTrials.gov
- Tested for
- NSAID (Non-Steroidal Anti-Inflammatory Drug), Gastric Ulcer, Healed Erosive Esophagitis
- Main trialPhase 4
- “The study aims to demonstrate the preventive effect of Fexuprazan 20 mg for peptic ulcer is non-inferior to that of Lansoprazole 15 mg in terms of prevention of peptic ulcer and confirm the safety of Fexuprazan 20 mg.”In the company’s words, NCT07533266 on ClinicalTrials.gov
- Other names
- DWP14012 · Fexuclue
Other drugs for Gastric Ulcer
- AD-115AAddpharma Inc. · Phase 1
Coming up3
- Dec 2027Phase 4 trial completes · ClinicalTrials.gov
- 15 Apr 2028Phase 3 trial completes · ClinicalTrials.gov
- Aug 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials16
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Not yet recruiting | Dec 2027 | Study to Evaluate the Efficacy and Safety of Fexuprazan in Prevention of NSAIDs Induced Peptic Ulcer | |
| Phase 3Not yet recruiting | 15 Apr 2028 | Phase 3 to Evaluate the Efficacy and Safety of DWP14012 in Patients With Gastric Ulcer | |
| Phase 3Not yet recruiting | Aug 2029 | Efficacy and Safety of DWP14012 for Long-Term Maintenance Therapy in Patients With Healed Erosive Esophagitis | |
| Phase 3Completed | 4 Aug 2021 | Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Acute or Chronic Gastritis | |
| Phase 3Completed | 23 Jul 2022 | The Efficacy and Safety of DWP14012 in Chinese Patients With Reflux Esophagitis | |
| Phase 3Completed | 27 Nov 2023 | Study to Evaluate the Efficacy and Safety of DWP14012 in Prevention of NSAIDs Induced Peptic Ulcer | |
| Phase 3Unknown | Jan 2025 | Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Non-Erosive Gastroesophageal Reflux Disease (NERD) | |
| Phase 3Completed | 24 Apr 2025 | Study to Evaluate the Efficacy and Safety of DWP14012-based Triple Therapy in Eradication of Helicobacter Pylori | |
| Phase 1Unknown | 30 Jun 2021 | Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Pharmacodynamics After Intravenous DWJ1521 Administration in Healthy Adult Volunteers | |
| Phase 1Completed | 26 Oct 2021 | Evaluate the Pharmacokinetics and Safety of DWP14012 Tablet A and Compare Those of DWP14012 Tablet B in Healthy Subjects | |
| Phase 1Completed | 29 Mar 2022 | Study to Evaluate the Safety/Tolerability, PK and PD After Intravenous DWJ1521 Administration in Healthy Volunteers | |
| Phase 1Completed | 22 May 2022 | Drug-drug Interactions Between DWP14012 and Aspirin in Healthy Subjects | |
| Phase 1Completed | 6 Mar 2023 | Drug-drug Interactions Between DWP14012 and DWC202202 in Healthy Subjects | |
| Phase 1Unknown | 28 Mar 2023 | Phase 1 Clinical Trial to Evaluate the Effect of DWP14012 on the Pharmacokinetics of DWC202201 in Healthy Subjects | |
| Phase 1Unknown | 31 May 2023 | A Clinical Study to Investigate the Mass Balance and Biotransformation of [14C]DWP14012 in Healthy Chinese Male Subjects | |
| Phase 1Unknown | Jan 2025 | to Evaluate the Safety/Tolerability and Pharmacokinetics, and Pharmacodynamics of DWP14012 Injection |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026